Yahyazadeh, A.Altunkaynak, B. Z.Alkan, IHistoloji ve Embriyoloji / Histology and Embriology2024-05-252024-05-25202040006-92481336-034510.4149/BLL_2020_1082-s2.0-85090941486https://doi.org/10.4149/BLL_2020_108https://hdl.handle.net/20.500.14517/1431OBJECTIVE: We aimed to investigate the possible effect of topiramate (TOP, 0.02 mg/kg/day) on the livers in a high-fat diet (HFD)-induced obesity rat model. The other objective was to evaluate the relationship between TOP administration and NPY level using anti-NPY1R antibody. METHODS: Twenty-four adult female Wistar albino rats were randomly assigned into four equal groups as follow: control (CONT), obese (OBS), TOP, and OBS+TOP. All liver samples were investigated using the stereological analysis, as well as immunohistochemical and histopathological examination. RESULTS: The total number of hepatocytes was significantly decreased in the OBS+TOP group compared to the CONT group or the OBS group (p < 0.05). We found a significant increase in the mean volume of liver in the OBS group compared to the CONT group (p < 0.05). Also, the mean volume of liver was significantly decreased in the OBS+TOP group compared to the OBS group (p < 0.05). CONCLUSION: Taken together, our findings suggest that decreased liver volume is possibly attributed to TOP administration via setting the NPY level in the obese rats. Further, the side effects of TOP in combination with health risk of obesity may have led to an increase in hepatotoxicity and the subsequent hepatocyte loss (Fig. 7, Ref. 56). Text in PDF www.elis.skeninfo:eu-repo/semantics/openAccessimmunohistochemistryliverneuropeptide YobesityrattopiramateArticleQ4Q21219656662WOS:00057157600000732990014